Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Lorenza Landi; Federica D'IncÃ; Alain Gelibter; Rita Chiari; Francesco Grossi; Angelo Delmonte; Antonio Passaro; Diego Signorelli; Francesco Gelsomino; Domenico Galetta; Diana Giannarelli; Hector Soto Parra; Gabriele Minuti; Marcello Tiseo; Maria Rita Migliorino; Francesco Cognetti; Luca Toschi; Paolo Bidoli; Francovito Piantedosi; Luana Calabro'; Federico Cappuzzo

doi:10.1186/s40425-019-0793-8

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Lorenza Landi, Federica D'IncÃ, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti, Luca Toschi, Paolo Bidoli, Francovito Piantedosi, Luana Calabro'Federico Cappuzzo

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. METHODS: Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. RESULTS: Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, pâ€‰

Original language	Italian
Pages (from-to)	316
Number of pages	1
Journal	Journal for ImmunoTherapy of Cancer
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/s40425-019-0793-8
Publication status	Published - 2019

Access to Document

10.1186/s40425-019-0793-8

https://www.ncbi.nlm.nih.gov/pubmed/31752994; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868703/

Cite this

Landi, L., D'IncÃ, F., Gelibter, A., Chiari, R., Grossi, F., Delmonte, A., Passaro, A., Signorelli, D., Gelsomino, F., Galetta, D., Giannarelli, D., Soto Parra, H., Minuti, G., Tiseo, M., Migliorino, M. R., Cognetti, F., Toschi, L., Bidoli, P., Piantedosi, F., ... Cappuzzo, F. (2019). Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. Journal for ImmunoTherapy of Cancer, 7(1), 316. https://doi.org/10.1186/s40425-019-0793-8

Landi, L, D'IncÃ, F, Gelibter, A, Chiari, R, Grossi, F, Delmonte, A, Passaro, A, Signorelli, D, Gelsomino, F, Galetta, D, Giannarelli, D, Soto Parra, H, Minuti, G, Tiseo, M, Migliorino, MR, Cognetti, F, Toschi, L, Bidoli, P, Piantedosi, F, Calabro', L & Cappuzzo, F 2019, 'Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer', Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, pp. 316. https://doi.org/10.1186/s40425-019-0793-8

@article{f0acd3dc696241bb8b77b9b89c87642a,

title = "Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer",

abstract = "BACKGROUND: Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. METHODS: Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. RESULTS: Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p{\^a}€‰",

keywords = "Bone metastases, Immunotherapy, Nivolumab, Non-small-cell lung cancer, PD-L1",

author = "Lorenza Landi and Federica D'Inc{\~A} and Alain Gelibter and Rita Chiari and Francesco Grossi and Angelo Delmonte and Antonio Passaro and Diego Signorelli and Francesco Gelsomino and Domenico Galetta and Diana Giannarelli and {Soto Parra}, Hector and Gabriele Minuti and Marcello Tiseo and Migliorino, {Maria Rita} and Francesco Cognetti and Luca Toschi and Paolo Bidoli and Francovito Piantedosi and Luana Calabro' and Federico Cappuzzo",

note = "undefined; J2: J Immunother Cancer M1 - Journal Article",

year = "2019",

doi = "10.1186/s40425-019-0793-8",

language = "Italian",

volume = "7",

pages = "316",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

AU - Landi, Lorenza

AU - D'IncÃ, Federica

AU - Gelibter, Alain

AU - Chiari, Rita

AU - Grossi, Francesco

AU - Delmonte, Angelo

AU - Passaro, Antonio

AU - Signorelli, Diego

AU - Gelsomino, Francesco

AU - Galetta, Domenico

AU - Giannarelli, Diana

AU - Soto Parra, Hector

AU - Minuti, Gabriele

AU - Tiseo, Marcello

AU - Migliorino, Maria Rita

AU - Cognetti, Francesco

AU - Toschi, Luca

AU - Bidoli, Paolo

AU - Piantedosi, Francovito

AU - Calabro', Luana

AU - Cappuzzo, Federico

N1 - undefined; J2: J Immunother Cancer M1 - Journal Article

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. METHODS: Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. RESULTS: Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, pâ€‰

AB - BACKGROUND: Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. METHODS: Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. RESULTS: Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, pâ€‰

KW - Bone metastases

KW - Immunotherapy

KW - Nivolumab

KW - Non-small-cell lung cancer

KW - PD-L1

U2 - 10.1186/s40425-019-0793-8

DO - 10.1186/s40425-019-0793-8

M3 - Articolo

VL - 7

SP - 316

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

ER -